2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Supplemental Data Press Release All Versions of this Article: ASN.2009030319v1 20/10/2223    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Chan, K. E. Articles by Hakim, R. M. PubMed PubMed Citation Articles by Chan, K. E. Articles by Hakim, R. M. Related Collections Related Articles

Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation

Kevin E. Chan^*, J. Michael Lazarus^*, Ravi Thadhani and Raymond M. Hakim^*

*Fresenius Medical Care NA, Waltham, Massachusetts; and
Nephrology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts

Correspondence: Dr. Kevin E. Chan, Fresenius Medical Care NA, 920 Winter Street, Waltham, MA 02451. Phone: 781-699-2546; Fax: 781-699-4047; E-mail: Kevin.chan{at}fmc-na.com

Received for publication March 20, 2009. Accepted for publication June 10, 2009.

Use of warfarin, clopidogrel, or aspirin associates with mortality among patients with ESRD, but the risk-benefit ratio may depend on underlying comorbidities. Here, we investigated the association between these medications and new stroke, mortality, and hospitalization in a retrospective cohort analysis of 1671 incident hemodialysis patients with preexisting atrial fibrillation. We followed patient outcomes from the time of initiation of dialysis for an average of 1.6 yr. Compared with nonuse, warfarin use associated with a significantly increased risk for new stroke (hazard ratio 1.93; 95% confidence interval 1.29 to 2.90); clopidogrel or aspirin use did not associate with increased risk for new stroke. Analysis using international normalized ratio (INR) suggested a dose-response relationship between the degree of anticoagulation and new stroke in patients on warfarin (P = 0.02 for trend). Warfarin users who received no INR monitoring in the first 90 d of dialysis had the highest risk for stroke compared with nonusers (hazard ratio 2.79; 95% confidence interval 1.65 to 4.70). Warfarin use did not associate with statistically significant increases in all-cause mortality or hospitalization. In conclusion, warfarin use among patients with both ESRD and atrial fibrillation associates with an increased risk for stroke. The risk is greatest in warfarin users who do not receive in-facility INR monitoring.

Related Articles

This Month's Highlights
J. Am. Soc. Nephrol. 2009 20: A12. [Full Text] [PDF]

This article has been cited by other articles:

				S. Genovesi and A. Santoro Warfarin and Stroke Outcomes in Hemodialysis Patients with Atrial Fibrillation J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2090 - 2092. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673